New Zealand Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

New Zealand Pharmaceuticals and Healthcare Report

New Zealand Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
New Zealand Pharmaceuticals and Healthcare Report
Published Aug 27, 2016
76 pages — Published Aug 27, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

New Zealand s FY----/-- budget released in May ---- allocated NZD--.-bn (USD--.-mn) ...Measures announced together with the budget include plans to roll out a bowel cancer screening programme and additional funds to provide access to new treatments. Starting from July - ----, the Pharmaceutical Management Agency will use the Factors for Consideration to replace the Decision Criteria. ...In August ----, New Zealand s Pharmaceutical Management Agency announced that it will be funding Keytruda (pembrolizumab) starting from September ----. According to the agency s operations director, Sarah Fitt, new information has emerged that gives them the confidence to proceed with the funding decision.

...BMI View: New Zealand s Pharmaceutical Management Agency (PHARMAC) will continue to leverage its dominant position as a central procurer of drugs in the country to drive cost savings. While the high standards used by the agency in its funding decisions will make the process difficult, PHARMAC does acknowledge innovation as reflected by the expedient approval of Opdivo (nivolumab). ...BMI View: New Zealand s Pharmaceutical Management Agency (PHARMAC) will continue to leverage its dominant position as a central procurer of drugs in the country to drive cost savings. While the high standards used by the agency in its funding decisions will make the process difficult, PHARMAC does acknowledge innovation as reflected by the expedient approval of Opdivo (nivolumab). This accentuates the need for multinational drugmakers operating in New Zealand to ensure that their treatments substantially improve healthcare outcomes. ...While the high standards used by the agency in its funding decisions will make the process difficult, PHARMAC does acknowledge innovation as reflected by the expedient approval of Opdivo (nivolumab). This accentuates the need for multinational drugmakers operating in New Zealand to ensure that their treatments substantially improve healthcare outcomes.

...All information contained in this publication is copyrighted in the name of Business Monitor International Ltd, and as such no part of this publication may be reproduced, repackaged, redistributed, resold in whole or in any part, or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping, or by information storage or retrieval, or by any other means, without the express written consent of the publisher. ...

...Commodification of generic drug sector will attract manufacturers from low-cost bases. The Trans-pacific partnership (TPP), once entered into force, is likely to reduce regulatory barriers and speed up the approval of high value pharmaceuticals and biologics for sale TPP also likely to restrain PHARMAC s ability to hold down prices Authorities commitment to tackling public health issues, such as the rising prevalence of infectious diseases. ...

  
Source:
Document ID
2047-9417
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "New Zealand Pharmaceuticals and Healthcare Report" Aug 27, 2016. Alacra Store. Dec 06, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/New-Zealand-Pharmaceuticals-and-Healthcare-Report-2026-1306>
  
APA:
Business Monitor International - Industry Reports. (2016). New Zealand Pharmaceuticals and Healthcare Report Aug 27, 2016. New York, NY: Alacra Store. Retrieved Dec 06, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/New-Zealand-Pharmaceuticals-and-Healthcare-Report-2026-1306>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.